Efficacy and safety of botulinum toxin type A for postoperative scar prevention and wound healing improvement: A systematic review and meta‐analysis

Fu, Ziyao; Huang, Hung-Lung; Huang, Jiuzuo

doi:10.1111/jocd.14617

Cited by 7 publications

(12 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Robotic-assisted or laparoscopic single-port surgery is wildly applied in various adult subspecialty [ 3 – 6 ]. And robotic-assisted single-port surgery is successfully used in pediatric pyeloplasty and cholecystectomy [ 7 , 8 ].…”

Section: Discussionmentioning

confidence: 99%

“…Operative data were recorded, including surgical site, whole operative time (skin to skin), trocar insertion time, Ureteral reimplantation time, blood loss, transfusions, and volumes. Postoperative and follow-up data were collected, including duration of fasting, duration of JJ tube and gastric tube use, duration of the ureteral catheter, postoperative SFU, change of pre-postoperative SFU, postoperative DRF, change of pre-postoperative DRF, postoperative APDRPU, change of pre-postoperative APDRPU, length of hospital stay, complications (urine leakage, infection, anastomotic stenosis), parents’ satisfaction scores to the surgical scar (Stony Brook Scar Evaluation Scale, SBSES) [ 3 ], and outcomes (3 months after surgery).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Single-port plus one in pediatric robotic-assisted Lich-Gregoir ureteral reimplantation for vesicoureteral reflux, a comparative analysis with short-term outcomes

Chen,

Kang,

Lin

et al. 2024

BMC Urol

View full text Add to dashboard Cite

Objective To observe the safety and short-term outcomes of a new way of laparoscopic trocar placement in pediatric robotic-assisted Lich-Gregoir ureteral reimplantation for vesicoureteral reflux. Methods The retrospective study included 32 patients under 14 years diagnosed with primary vesicoureteral reflux (VUR). All these patients underwent robotic-assisted Lich-Gregoir ureteral reimplantation in our department from December 2020 to August 2022. These patients were divided into the following groups according to the different ways of trocar placement: 13 patients in group single-port plus one (SR) and 19 patients in group multiple-port (MR). Patients’ characteristics as well as their perioperative and follow-up data were collected and evaluated. Results There was no significant difference in the data regarding patients’ characteristics and preoperative data. These data included the grade of vesicoureteral reflux according to the voiding cystourethrogram (VCUG), and the differential degree of renal function (DRF) at the following time points: preoperative, postoperative, and comparison of preoperative and postoperative. There was no difference between the two groups. During surgery, the time of artificial pneumoperitoneum establishment, ureteral reimplantation time, and total operative time in the SR group were longer than those in the MR group. Yet only the time of artificial pneumoperitoneum establishment shows a statistical difference (P < 0.0001). Also, the peri-operative data, including the volume of blood loss, fasting time, hospitalization, and length of time that a ureteral catheter remained in place, and the number of postoperative complications demonstrate no difference. In addition, the SFU grade and VCUG grade at the following time point also show no difference between the two groups. Conclusion The study demonstrates that SR in robotic-assisted Lich-Gregoir ureteral reimplantation has reached the same surgical effects as MR. In addition, the single-port plus one trocar placement receives a higher cosmetic satisfaction score from parents and did not increase the surgical time and complexity.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Single-port plus one in pediatric robotic-assisted Lich-Gregoir ureteral reimplantation for vesicoureteral reflux, a comparative analysis with short-term outcomes

Chen,

Kang,

Lin

et al. 2024

BMC Urol

View full text Add to dashboard Cite

show abstract

“…Some preliminary research suggests that BTXA may influence scar formation by reducing fibroblast proliferation, decreasing TGF expression, and altering collagen deposition and remodeling processes 20,21 . Many reviews and meta‐analyses have been conducted to support the effectiveness of BTXA in scar treatment 22–24 . Guo et al 25 concluded that BTXA injection can improve general scar quality and wound healing in the face and neck in Asians.…”

Section: Discussionmentioning

confidence: 99%

“…20,21 Many reviews and meta-analyses have been conducted to support the effectiveness of BTXA in scar treatment. [22][23][24] Guo et al 25 concluded that BTXA injection can improve general scar quality and wound healing in the face and neck in Asians. However, different anatomical locations have various propensities to scar formation, and orbicularis oris derives from eight muscle components with their origins in the modiolus at each angle of the mouth.…”

Section: Discussionmentioning

confidence: 99%

Botulinum toxin type A for preventing and treating cleft lip scarring—A systematic review and meta‐analysis

Tang

et al. 2022

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Background Cleft lip and/or palate (CL/P) are congenital cleft facial deformities that are abnormal developments caused by errors in the fusion process of the embryo's face. Surgery is an important treatment, but postoperative scars will still cause psychological shadows to patients. This study aimed to systematically evaluate the efficacy of Botulinum toxin type A (BTXA) in preventing and treating postoperative CL/P scars and improving scar quality. Methods A systematic review was performed by searching PubMed, EMBASE, the Cochrane Library, and Web of Science for relevant trials. All relevant trials were performed before June 30, 2021. The data were entered into Revman 5.3 software, and a meta‐analysis was conducted by using the random‐effects model or fixed‐effects model. Results Four randomized controlled trials involving 161 cases were included. Through quantitative analysis, BTXA showed significant differences in preventing and treating postoperative CL/P scars in terms of scar width (MD: −0.20; [95% CI, −0.30, –0.10], p < 0.0001) and the Visual Analog Scale (VAS) (MD: 1.30; [95% CI, 1.06, 1.55], p < 0.0001), although no significant difference was noted on the Vancouver Scar Scale (VSS) (MD: −0.75; [95% CI, −1.68, 0.19], p = 0.12) between the two groups. Conclusion In preventing and treating postoperative CL/P scar hypertrophy, we found that BTXA injection can show better results. There was no statistically significant difference between the results after omitting Navarro's study or Chang's study because of the time of injection—before/during surgery or adult CL/P scars.

show abstract

“…Of the four serotypes that infect humans, botulinum neurotoxin A (BoNT/A1) is the most potent followed by serotypes B (BoNT/B), E (BoNT/E) and F (BoNT/F) 11 . Notwithstanding the lethality of this agent, BoNTs are widely exploited in the medical domain to treat a broad range of neurological disorders as well as in the field of cosmetics [12][13][14] BoNTs are composed of two domains comprising a 50 kDa light chain (LC) and a 100 kDa heavy chain (HC). The LC is the catalytic domain of BoNTs.…”

Section: Introductionmentioning

confidence: 99%

Structural basis of botulinum neurotoxin serotype A1 binding to human SV2A or SV2C receptors

Azzaz

Hilaire

Fantini

2022

Preprint

View full text Add to dashboard Cite

Botulinum neurotoxin A1 (BoNT/A1) is the most potent serotype in humans with the highest clinical duration. BoNT/A1 interacts with synaptic vesicle glycoprotein 2 (SV2) and gangliosides to be taken up by neurons. In this study, we present three molecular dynamics simulations in which BoNT/A1 is in complex with singly or doubly glycosylated SV2C or singly glycosylated SV2A, in a ganglioside rich (lipid raft) context. Our computational data suggest that the N-glycan at position 480 (N480g) in the luminal domain of SV2C (LD-SV2C) indirectly enhanced the contacts of the neurotoxin surface with the second N-glycan at position 559 (N559g) by acting as a shield to prevent N559g to interact with residues of LD-SV2C. The N-glycosylation at the position N573 (N573g) in the luminal domain of SV2A has a slightly lower affinity for the surface of BoNT/A1 compared to 559g because of possible intermolecular contacts between N573g and residues of the luminal domain of SV2A (LD-SV2A). In addition to the ganglioside binding site (GBS) conserved across serotypes B, E, F and G, the lipid-raft associated GT1b interacted with a structure we coined the ganglioside binding loop (GBL) which is homologous to the lipid binding loop (LBL) in serotypes B, C, D, D/C and G. Finally, we proposed a global model in which BoNT/A1 interacts with its glycosylated protein receptor, one molecule of GT1b interacting in the GBS and five molecules of GT1b interacting with the GBL and residue Y1133.

show abstract

Efficacy and safety of botulinum toxin type A for postoperative scar prevention and wound healing improvement: A systematic review and meta‐analysis

Cited by 7 publications

References 84 publications

Single-port plus one in pediatric robotic-assisted Lich-Gregoir ureteral reimplantation for vesicoureteral reflux, a comparative analysis with short-term outcomes

Single-port plus one in pediatric robotic-assisted Lich-Gregoir ureteral reimplantation for vesicoureteral reflux, a comparative analysis with short-term outcomes

Botulinum toxin type A for preventing and treating cleft lip scarring—A systematic review and meta‐analysis

Structural basis of botulinum neurotoxin serotype A1 binding to human SV2A or SV2C receptors

Contact Info

Product

Resources

About